What are the benefits and harms of adjuvant chemotherapy in people with resected early-stage non-small cell lung cancer?

2018 ◽  
Author(s):  
Sera Tort ◽  
John C Ruckdeschel
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer

2009 ◽  
Vol 4 (7) ◽  
pp. 891-910 ◽  
Author(s):  
Ana Belén Custodio ◽  
José Luis González-Larriba ◽  
Jana Bobokova ◽  
Antonio Calles ◽  
Rafael Álvarez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Predictive Markers ◽  
Small Cell Lung ◽  
Prognostic And Predictive Markers

Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients

2020 ◽  
Vol 11 (7) ◽  
pp. 1145-1153
Author(s):  
Madison Grinnell ◽  
Adams Kusi Appiah ◽  
Michael Baine ◽  
Vinicius Ernani ◽  
Alissa Marr ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Older Patients ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

Effect of age on impact of adjuvant chemotherapy for resected non-small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7539-7539
Author(s):  
Apar Kishor Ganti ◽  
Christina D. Williams ◽  
Ajeet Gajra ◽  
Michael J. Kelley
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Older Patients ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Younger Patients ◽  
Stage 1

7539 Background: Adjuvant chemotherapy (AC) is considered standard of care in patients with resected stages 2 and 3 non-small cell lung cancer (NSCLC). However data regarding its utility in older patients are sparse. This analysis was conducted to evaluate the role of AC in older patients with early stage NSCLC. Methods: We conducted a retrospective analysis of patients with stages 1-3 NSCLC between 2001 and 2008 in the VA Central Cancer Registry. Patients were divided into two groups based on age: <70 yrs and ≥70 yrs. Descriptive statistics were used to examine patterns of AC use and to obtain survival rates associated with use of AC in the two age groups. Chi-square was used to compare distributions. Results: Of the 10,036 patients who underwent surgical resection, 3958 (39.4%) were ≥70 yrs, while 6078 were <70 yrs old. Overall, 11.2% of older patients (6.3% - stage 1, 21% - stage 2, 26.2% - stage 3) and 22.3% of younger pts (11.6% - stage 1, 41.1% - stage 2, 47.1% - stage 3) received AC. Of the patients who received AC, a greater proportion of younger patients received platinum-based AC (91.8 vs 86.4% vs; p=0.0008). Also, in each stage younger patients had a better 3 yr overall survival (OS) (Stage 1-69.2 vs 58%, stage 2 – 52.8 vs 39.1%, stage 3 – 42.5 vs 33.7%). Younger patients with stages 2 and 3 NSCLC who received AC had improved 3 yr OS (58.8 vs 48.6%; p=0.0009 and 48.8 vs 36.9%; p=0.0002 respectively). There was no difference in 3 yr OS for older patients based on AC when all stages were included. For patients with stages 2 and 3, a larger proportion of younger patients received cisplatin-based AC (11.3 vs 3.5%). Older patients with stages 2 and 3, who received cisplatin-based AC had a better 3 yr OS compared to those who received carboplatin-based AC or no AC (55.3 vs 42.2 vs 35.3% respectively; p=0.01). Similarly cisplatin-based AC had an improved 3 yr OS in younger patients with stages 2 and 3 NSCLC (61.4 vs 52 vs 43.4% respectively; p=0.0001). Conclusions: This analysis suggests that older patients do not benefit from AC after resection of stage 1-3 NSCLC to the same degree as younger patients. This differential effect may be due to less common use of cisplatin among older patients. Multivariate analyses are planned.

PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 12059-12059
Author(s):  
Jennifer Bordeaux ◽  
Naveen Dakappagari ◽  
Nathan A. Pennell ◽  
James Stevenson ◽  
Monica Khunger ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Survival Benefit ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document